•  
• Tweet
•  
•        Print
•  
•         Track Keywords
•  
• 

Laxman Pai, Opalesque Asia:

HealthCare Royalty Partners, a global healthcare investment firm with $5.5 billion of cumulative capital commitments, announced the closing on $1.83 billion for HealthCare Royalty Partners IV (Fund IV) and affiliated entities.

Since 2003, HCR's senior professionals have invested over $3.0 billion in commercial or near-commercial stage biopharmaceutical products through the purchase of royalties, revenue interests, and credit instruments.

Fund IV, like HCR's predecessor funds, will seek to continue to provide investors with returns that are non-correlated to the broader equity or credit markets.

HCR said that many of its existing investors came back into Fund IV. It also welcomed new investors representing several of the world's leading pensions, sovereign wealth funds, financial institutions, foundations and family offices.

"The strong support from investors in the U.S., U.K., Europe, Australia, Middle East, and Africa, demonstrates the growing acceptance of pharmaceutical royalties as a supplement to traditional fixed income/credit / absolute return portfolios," it said.

"Increasing investor demand for non-correlated, yielding assets aligns well with HCR's strategy, as evidenced by the capital committed to Fund IV. HCR's regional sourcing strategy and deep bench of in-house scientists have generated strong results for HCR's predecessor fund, which we believe will continue for Fund IV," said Clarke B. Futch, Managing Partner an......................

To view our full article Click here